PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34222724-0 2021 Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis. Xanthine 15-23 dipeptidyl peptidase 4 Homo sapiens 30-52 27560285-0 2016 Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Xanthine 19-27 dipeptidyl peptidase 4 Homo sapiens 48-54 27180612-3 2017 Linagliptin has a xanthine-based structure, a difference that might account for some of the pharmacological differences observed with linagliptin versus other dipeptidyl-peptidase-4 inhibitors. Xanthine 18-26 dipeptidyl peptidase 4 Homo sapiens 159-181 27560285-1 2016 A series of xanthine derivatives as potent dual ligands targeting DPP-IV and GPR119 was discovered through an approach of the merged pharmacophores of GPR119 agonists and DPP-IV inhibitor linagliptin. Xanthine 12-20 dipeptidyl peptidase 4 Homo sapiens 66-72 27560285-1 2016 A series of xanthine derivatives as potent dual ligands targeting DPP-IV and GPR119 was discovered through an approach of the merged pharmacophores of GPR119 agonists and DPP-IV inhibitor linagliptin. Xanthine 12-20 dipeptidyl peptidase 4 Homo sapiens 171-177 24900744-0 2013 Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery. Xanthine 48-56 dipeptidyl peptidase 4 Homo sapiens 63-67 29879349-1 2016 In order to find more potential DPP-IV inhibitor, a series of xanthine-scaffold analogs of linagliptin, an approved antidiabetes drug, were designed and synthesized for SAR study. Xanthine 62-70 dipeptidyl peptidase 4 Homo sapiens 32-38 25065332-0 2014 Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Xanthine 15-23 dipeptidyl peptidase 4 Homo sapiens 30-52 25756669-1 2014 Xanthine-based molecules such as serine protease dipeptidyl peptidase 4 (DPP4) inhibitors are compounds often used in improving glycemic control in type 2 diabetic patients and also used for their effects as mild stimulants and as bronchodilators, notably in treating asthma symptoms. Xanthine 0-8 dipeptidyl peptidase 4 Homo sapiens 49-71 25756669-1 2014 Xanthine-based molecules such as serine protease dipeptidyl peptidase 4 (DPP4) inhibitors are compounds often used in improving glycemic control in type 2 diabetic patients and also used for their effects as mild stimulants and as bronchodilators, notably in treating asthma symptoms. Xanthine 0-8 dipeptidyl peptidase 4 Homo sapiens 73-77 25756669-2 2014 Here, we aim to better understand the molecular features affecting activity of xanthine-based DPP4 inhibitors such as sitagliptin and related compounds and use these features to de novo predict improved sitagliptin derivatives. Xanthine 79-87 dipeptidyl peptidase 4 Homo sapiens 94-98 24481594-0 2014 Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4. Xanthine 70-78 dipeptidyl peptidase 4 Homo sapiens 94-99 24481594-1 2014 We apply molecular docking, molecular dynamics (MD) simulation, and binding free energy calculation to investigate and reveal the binding mechanism between five xanthine inhibitors and DPP-4. Xanthine 161-169 dipeptidyl peptidase 4 Homo sapiens 185-190 23305140-1 2013 The article describes the development of a robust pharmacophore model and the investigation of structure activity relationship analysis of 46 xanthine derivatives reported for DPP-IV inhibition using PHASE module of Schrodinger software. Xanthine 142-150 dipeptidyl peptidase 4 Homo sapiens 176-182 23748509-4 2013 RESULTS AND CONCLUSION: Linagliptin is a xanthine-based, oral DPP-4 inhibitor that has been approved in the United States and Europe. Xanthine 41-49 dipeptidyl peptidase 4 Homo sapiens 62-67 21916836-0 2011 Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. Xanthine 21-29 dipeptidyl peptidase 4 Homo sapiens 36-58 23358258-0 2013 Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. Xanthine 39-47 dipeptidyl peptidase 4 Homo sapiens 63-85 23358258-1 2013 A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes. Xanthine 12-20 dipeptidyl peptidase 4 Homo sapiens 149-171 23358258-1 2013 A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes. Xanthine 12-20 dipeptidyl peptidase 4 Homo sapiens 173-178 23358258-1 2013 A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes. Xanthine 84-92 dipeptidyl peptidase 4 Homo sapiens 173-178 22420306-12 2012 X-ray crystallography anticipates that Linagliptin complexes with human DPPIV enzyme, e.g. butynyl substituent occupies the S1 hydrophobic pocket of the enzyme; the aminopiperidine substituent in the xanthine scaffold occupies the S2 subsite and its primary amine interacts with the key amino acid residues, which involves in the recognition of peptide substrates. Xanthine 200-208 dipeptidyl peptidase 4 Homo sapiens 72-77 18052023-1 2007 A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Xanthine 78-86 dipeptidyl peptidase 4 Homo sapiens 31-36 19426127-1 2009 BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. Xanthine 11-19 dipeptidyl peptidase 4 Homo sapiens 26-31 18485703-1 2008 Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors. Xanthine 29-37 dipeptidyl peptidase 4 Homo sapiens 230-235 19947894-0 2010 Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Xanthine 15-23 dipeptidyl peptidase 4 Homo sapiens 30-52 19947894-4 2010 Linagliptin belongs to a new chemical class of dipeptidyl pepidase-4 (DPP-4) inhibitors, which comprise xanthine-based compounds. Xanthine 104-112 dipeptidyl peptidase 4 Homo sapiens 47-68 19947894-4 2010 Linagliptin belongs to a new chemical class of dipeptidyl pepidase-4 (DPP-4) inhibitors, which comprise xanthine-based compounds. Xanthine 104-112 dipeptidyl peptidase 4 Homo sapiens 70-75 17352678-1 2007 Xanthines and xanthine-like DPP-IV inhibitors were first disclosed in 2002. Xanthine 14-22 dipeptidyl peptidase 4 Homo sapiens 28-34 17352678-2 2007 Since then, several dozen accounts of xanthine-based DPP-IV inhibitors have been published. Xanthine 38-46 dipeptidyl peptidase 4 Homo sapiens 53-59